Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
MAPK9
REST API REST API
Homo sapiens
MAPK9 is differentially expressed in 329 experiments: 140 organism parts: cerebellum, amygdala, ... (138 more);, 184 disease states: normal, prostate carcinoma, ... (182 more);, 96 cell types 438 cell lines 43 compound treatments and 82 other conditions.
Synonyms SAPK, PRKM9, JNK2, p54a
Orthologs HOG1 (Saccharomyces cerevisiae)   Q4H3A2_CIOIN (Ciona intestinalis)   Q2KI72_BOVIN (Bos taurus)   Mapk9 (Rattus norvegicus)   Mapk9 (Mus musculus)   MK09_CHICK (Gallus gallus)   MAPK9 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term Toll signaling pathway, cytosol, JUN kinase activity, protein binding, phosphotransferase activity, alcohol group as acceptor, JUN phosphorylation, innate immune response, positive regulation of gene expression, membrane, response to stress, protein tyrosine kinase activity, stress-activated MAPK cascade, MAP kinase activity, transcription factor binding, response to cadmium ion, ATP binding, transferase activity, transferring phosphorus-containing groups, nucleotide binding, kinase activity, protein serine/threonine kinase activity, JNK cascade, nucleoplasm, catalytic activity, lipopolysaccharide biosynthetic process, protein kinase activity, mitochondrion, toll-like receptor 4 signaling pathway, positive regulation of macrophage derived foam cell differentiation, toll-like receptor signaling pathway, toll-like receptor 3 signaling pathway, toll-like receptor 2 signaling pathway, induction of apoptosis in response to chemical stimulus, MyD88-dependent toll-like receptor signaling pathway, protein phosphorylation, MyD88-independent toll-like receptor signaling pathway, regulation of sequence-specific DNA binding transcription factor activity, toll-like receptor 1 signaling pathway
InterPro Term Prot_kinase_cat_dom, RIO-like_kinase, JNK_MAPK, LipoPS_kinase, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Se/Thr_kinase-like_dom
UniProt Accession B5M0B4, D7R525, P45984, E5RJ57, D7R528
Search EB-eye ENSG00000050748
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, ... (28 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, E-GEOD-19639, ... (45 experiments)

Factor Value U/D Experiments
SW480
4
E-MEXP-1014, E-MTAB-37, E-GEOD-18005, E-GEOD-2509
BT474
3
E-MTAB-37, E-MEXP-440, E-MTAB-62
K562
3
E-GEOD-24147, E-GEOD-96, E-MTAB-37
HL-60
2
E-GEOD-24147, E-GEOD-5258
MCF-10A
2
E-TABM-420, E-GEOD-14990
MCF7
2
E-GEOD-5258, E-MTAB-37
432 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-19397, E-GEOD-21668, E-GEOD-3920, E-GEOD-360, ... (47 experiments)

Factor Value U/D Experiments
induced pluripotent stem cell
2
E-GEOD-18265, E-GEOD-18147
CD34+
2
E-AFMX-5, E-TABM-145
human embryonic stem cell
2
E-GEOD-18265, E-GEOD-18147
erythropoietic
1
E-GEOD-9894
spheroid recovery
1
E-GEOD-4219
adipose stem cells derived from adult human donor
1
E-GEOD-20033
90 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-MEXP-2280, E-MTAB-62, ... (61 experiments)

Factor Value U/D Experiments
control
3
E-GEOD-21912, E-GEOD-8121, E-GEOD-20295
cervical carcinoma
2
E-MTAB-62, E-MTAB-37
choriocarcinoma
2
E-MTAB-37, E-MTAB-62
colon carcinoma
2
E-MTAB-62, E-MTAB-37
lung adenocarcinoma
2
E-MTAB-62, E-MTAB-37
malaria
1
E-MTAB-62
178 more value(s).


Compound treatment

studied in E-TABM-782, E-GEOD-3720, E-GEOD-5824, E-TABM-868, E-MEXP-1958, ... (29 experiments)

Factor Value U/D Experiments
lipopolysaccharide
3
E-MEXP-1958, E-GEOD-3720, E-TABM-868
dimethyl sulfoxide
2
E-GEOD-5824, E-GEOD-6932
NaOH
1
E-MEXP-2590
mercaptopurine, methotrexate
1
E-GEOD-412
nocodazole
1
E-GEOD-571
vanadium pentoxide
1
E-GEOD-5339
37 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
tunicamycin
1
1
E-GEOD-19519
DMSO
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519


Biosource provider
studied in E-TABM-325, E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-TABM-36, E-MEXP-1251, E-GEOD-1563, ... (8 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-3140, E-MEXP-2359, E-GEOD-6236, E-GEOD-2666, E-GEOD-4667, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-3325, E-GEOD-2509, E-GEOD-22148, ... (10 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-4025, E-MEXP-1482, E-GEOD-7578, ... (10 experiments)

Genotype
studied in E-TABM-1029, E-MEXP-1996, E-GEOD-17476, E-GEOD-22593, E-TABM-868, ... (13 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, E-GEOD-10315, E-GEOD-837, ... (14 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-MEXP-1648, ... (38 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-980, ... (6 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Karyotype
studied in E-GEOD-7214, E-GEOD-22056

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-AFMX-1, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-1309, E-GEOD-21750, E-GEOD-17636

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10797, E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, ... (9 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-MEXP-70, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-1643, E-GEOD-7540, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-MEXP-973, E-GEOD-19246, ... (8 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-TABM-43, E-GEOD-1561, E-GEOD-4922

Tumor size
studied in E-GEOD-3494, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.246 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM